Clinical Trial

Motion Sickness Severity and Sensorimotor Performance

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated June 26, 2026 (before its estimated August 2, 2026 completion). Its status may not reflect the trial's current state.
Summary
Background: Motion sickness (MS) is a common syndrome characterized by autonomic and behavioral symptoms, such as nausea and dizziness, resulting from exposure to motion stimuli. Its pathophysiology is closely linked to sensory conflict and postural instability theories. While previous studies suggest that postural control, proprioception, and reaction times are affected in individuals susceptible to MS, there is a lack of comprehensive, comparative research evaluating all these parameters concurrently within the same cohort using standardized methods. Objective: This study aims to systematically measure balance, proprioceptive sensitivity, coordination, and reaction time parameters, and quantitatively analyze their relationship with motion sickness severity. Methodology: In this prospective, cross-sectional study, at least 41 participants aged 18-40 with motion sickness will be recruited. Participants will undergo motion sickness susceptibility and severity grading using the Motion Sickness Susceptibility Questionnaire Short Form (MSSQ-SF) and the Graybiel Scale. Objective assessments will include static and dynamic balance testing (ProKin®), knee joint position sense (Clinometer app), manual dexterity and dynamic balance coordination (Nine-Hole Peg Test, Tandem Walk, Romberg Test), and upper/lower extremity reaction time measurements (BlazePod system).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-05-26.
Trial Details
NCT Number NCT07619469
Lead Sponsor Istinye University
Conditions Motion Sickness, Somatosensory Disorders, Dizziness
Enrollment 41 participants
Start Date 2026-06-01
Primary Completion 2026-08-02 (estimated)
Study Completion 2026-08-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-26